Binding profile of protein–ligand inhibitor complex and structure based design of new potent compounds via computer-aided virtual screening

Gideon Adamu Shallangwa *,1, Shola Elijah Adeniji 2

Department of Chemistry, Ahmadu Bello University Zaria, Kaduna State, Nigeria

ARTICLE INFO

Keywords: DNA gyrase Quinoline Tuberculosis

ABSTRACT

Background: Mycobacterium tuberculosis protein target (DNA gyrase) is a type II topoisomerase target present in all bacteria. The enzyme comprises of two subunits A and B. DNA binding domain is located in the subunits A while the catalysis and cleavage of two DNA strands occur in the subunits A using ATP hydrolysis. This enzyme has been reported to emerge in extensively drug resistant tuberculosis. Therefore this research aimed to design new potent compounds against the target and establish the analysis of protein–ligand binding interaction between the target and novel quinoline analogues via the application of in silico virtual screening to predict the inhibition binding affinities the analogues.

Result: The docking results revealed that compound ID 17 with efficient inhibition activity has a noticeable binding affinity of ~18.8 kcal/mol. Hence compound 17 was designated as the reference template to designed novel fourteen compounds with higher binding affinities as a promising compounds.

Conclusion: Designed compound 17i, 17j and 17n with lead binding affinities among the designed compounds were observed with the most perceptible binding affinity which ranges from (~21.2 to ~26.8) kcal/mol compared to low binding affinity (~5.8 kcal/mol) computed for ethambutol.

1. Background

The discovery of more potent agents against the resistance strain of tuberculosis has been a serious challenge for chemist and the pharmacist [1]. The challenge of patient not giving positive response when administered with anti-tubercular drugs as a result of resistance strain of M. tuberculosis has been widely reported in literature [1,2]. The difficulty to fight against this disease has caused a serious challenge to scientist. Therefore, this problem has necessitate for the development of more potent drugs to combat the resistance or new wave of tuberculosis with minima side effects [1,3].

DNA gyrase i.e. type II topoisomerase target, relaxes the translocation of RNA polymerase by creating negative supercoils which reduced the chromosome for appropriate segregating during cell division [1,4,5]. This enzyme breaks and reunite the DNA strand via subunit A i.e. GyrA while the activities of the ATP binding take place at subunit B i.e. GyrB. Reference to these functions, the DNA replication activities can be terminated by using a potent inhibitor to block either of the DNA gyrase active site i.e. GyrA or GyrB respectively.

Several reports have make reference to quinoline and its analogues to have significant applications in medical and pharmacological therapy [3,6]. Current studies have also revealed the importance of quinoline’s structure and properties as a major bio-active molecule in pharmaceutical file mainly in drug discovery, delivery and design. Hence, this makes quinoline to gain massive attention and consideration among the scientist [1,7]. Interestingly, some findings also supported quinoline as a prominent anti-tubercular and analgesic agent [2,8].

Reference to the aforesaid problem, a computational approach has the potential to solve the challenges related to the issue of developing new potent drugs against M. Tuberculosis. This methods help in; reducing the constraint and requirement for prolonged and costly animal tests, and eventually gives idea and approach toward the successful discovery and development of novel drugs candidate with better activities [2].

Discovery of novel anti-tubercular inhibitors in the field of medical and pharmaceutical chemistry has been successfully established via computer-aided drug design. [9]. The advancement of this method has been expedited with definite resolutions during the optimization of chemical structures. [10].
| S/N | Molecular structure | Compound nomenclature | Percentage inhibition (%) |
|-----|---------------------|-----------------------|---------------------------|
| 1   | ![Molecular structure](image1) | (E)-2-((2-(2-methylpropylidene)hydrazinyl)-N-phenylquinoline-4-carboxamide | 11 |
| 2   | ![Molecular structure](image2) | (E)-N-phenyl-2-((2-propylidenehydrazinyl)quinoline-4-carboxamide | 12 |
| 3   | ![Molecular structure](image3) | (E)-2-((2-benzylidenehydrazinyl)-N-phenylquinoline-4-carboxamide | 11 |
| 4   | ![Molecular structure](image4) | (E)-2-((2-(4-methoxybenzylidene)hydrazinyl)-N-phenylquinoline-4-carboxamide | 23 |
| 5   | ![Molecular structure](image5) | (E)-2-((2-(4-methoxybenzylidene)hydrazinyl)-N-phenylquinoline-4-carboxamide | 14 |
| 6   | ![Molecular structure](image6) | (E)-N-benzyl-2-((2-(pyridin-3-ylmethylene)hydrazinyl)quinoline-4-carboxamide | 23 |
| 7   | ![Molecular structure](image7) | (E)-N-benzyl-2-((2-(furan-2-ylmethylene)hydrazinyl)quinoline-4-carboxamide | 20 |

(continued on next page)
| S/N | Molecular structure | Compound nomenclature                                                                 | Percentage inhibition (%) |
|-----|--------------------|--------------------------------------------------------------------------------------|----------------------------|
| 8   | ![Molecule](image1.png) | (E)-N-benzyl-2-((2-(thiophen-2-ylmethylene)hydrazinyl)quinoline-4-carboxamide)        | 85                         |
| 9   | ![Molecule](image2.png) | (E)-2-((2-(anthracen-9-ylmethylene)hydrazinyl)N-benzylquinoline-4-carboxamide)        | 20                         |
| 10  | ![Molecule](image3.png) | (E)-N-benzyl-2-((2-((4-methoxynaphthalen-1-yl)methylene)hydrazinyl)quinoline-4-carboxamide) | 16                         |
| 11  | ![Molecule](image4.png) | (E)-N-benzyl-2-((2-(2-methylpropylidene)hydrazinyl)quinoline-4-carboxamide)            | 42                         |
| 12  | ![Molecule](image5.png) | (E)-N-benzyl-2-((2-propylidenehydrazinyl)quinoline-4-carboxamide)                      | 27                         |

(continued on next page)
| S/N | Molecular structure | Compound nomenclature                                                                 | Percentage inhibition (%) |
|-----|---------------------|--------------------------------------------------------------------------------------|---------------------------|
| 13  | (E)-2-((2-(furan-2-ylmethylene)hydrazinyl)-N-(5-phenylpentyl)quinoline-4-carboxamide | 15                                                                                   |
| 14  | (E)-N-benzyl-2-((2-(4-methoxybenzylidene)hydrazinyl)quinoline-4-carboxamide         | 21                                                                                   |
| 15  | (E)-N-(5-phenylpentyl)-2-((2-(pyridin-4-ylmethylene)hydrazinyl)quinoline-4-carboxamide | 30                                                                                   |
| 16  | (E)-N-(5-phenylpentyl)-2-((2-(pyridin-3-ylmethylene)hydrazinyl)quinoline-4-carboxamide | 10                                                                                   |
| 17  | (E)-N-benzyl-2-((2-benzylidenehydrazinyl)quinoline-4-carboxamide                  | 99                                                                                   |

(continued on next page)


| S/N | Molecular structure | Compound nomenclature                                                                 | Percentage inhibition (%) |
|-----|---------------------|---------------------------------------------------------------------------------------|---------------------------|
| 18  | ![Molecular Structure](image1) | (E)-N-(5-phenylpentyl)-2-((2-(thiophen-2-ylmethylen)hydrazinyl)quinoline-4-carboxamide | 21                         |
| 19  | ![Molecular Structure](image2) | (Z)-2-((2-(anthracen-9-ylmethylen)hydrazinyl)-N-(5-phenylpentyl)quinoline-4-carboxamide | 23                         |
| 20  | ![Molecular Structure](image3) | (E)-2-((2-((4-methoxynaphthalen-1-yl)methylene)hydrazinyl)-N-(5-phenylpentyl)quinoline-4-carboxamide | 40                         |
| 21  | ![Molecular Structure](image4) | (E)-2-((2-(2-methylpropylidene)hydrazinyl)-N-(5-phenylpentyl)quinoline-4-carboxamide | 42                         |
| 22  | ![Molecular Structure](image5) | (E)-2-((2-benzylidenehydrazinyl)-N-(5-phenylpentyl)quinoline-4-carboxamide | 21                         |
| 23  | ![Molecular Structure](image6) | (E)-2-((2-(4-methoxybenzylidene)hydrazinyl)-N-(5-phenylpentyl)quinoline-4-carboxamide | 40                         |

(continued on next page)
### Table 1 (continued)

| S/ N | Molecular structure | Compound nomenclature | Percentage inhibition (%) |
|------|---------------------|------------------------|---------------------------|
| 24   | ![Molecular structure](image1.png) | (E)-(2-(2-((4-methoxynaphthalen-1-yl)methylene)hydrazinyl)quinolin-4-yl)(morpholino)methanone | 7 |
| 25   | ![Molecular structure](image2.png) | (E)-(2-(2-benzylidenehydrazinyl)quinolin-4-yl)(morpholino)methanone | 3 |
| 26   | ![Molecular structure](image3.png) | (E)-(2-(2-(4-methoxybenzylidene)hydrazinyl)quinolin-4-yl)(morpholino)methanone | 10 |
| 27   | ![Molecular structure](image4.png) | (E)-(4-methylpiperazin-1-yl)((2-(2-(pyridin-4-yl)methylene)hydrazinyl)quinolin-4-yl)methanone | 28 |
| 28   | ![Molecular structure](image5.png) | (E)-(2-(2-(furan-2-yl)methylene)hydrazinyl)quinolin-4-yl)(4-methylpiperazin-1-yl)methanone | 21 |

(continued on next page)
| S/ N | Molecular structure | Compound nomenclature                                                                 | Percentage inhibition (%) |
|------|--------------------|--------------------------------------------------------------------------------------|---------------------------|
| 29   | ![Molecule 29](image1.png) | (E)-(4-methylpiperazin-1-yl)((2-(2-(thiophen-2-ylmethylene)hydrazinyl)quinolin-4-yl)methanone | 10                        |
| 30   | ![Molecule 30](image2.png) | (E)-((2-(2-(anthracen-9-ylmethylene)hydrazinyl)quinolin-4-yl)(4-methylpiperazin-1-yl)methanone | 10                        |
| 31   | ![Molecule 31](image3.png) | (E)-((2-(2-((4-methoxynaphthalen-1-yl)methylene)hydrazinyl)quinolin-4-yl)(4-methylpiperazin-1-yl)methanone | 18                        |
| 32   | ![Molecule 32](image4.png) | (E)-(4-methylpiperazin-1-yl)((2-(2-(2-methylpropylidene)hydrazinyl)quinolin-4-yl)methanone | 52                        |
| 33   | ![Molecule 33](image5.png) | (E)-((2-(2-benzylidenehydrazinyl)quinolin-4-yl)(4-methylpiperazin-1-yl)methanone            | 9                         |

(continued on next page)
The knowledge of molecular docking simulation has been widely exploited to develop, design and synthesis new compounds with enhance efficacy against tuberculosis via computer-aided drug technique in the areas of drug discovery [2]. Molecular docking aid to forecast the interactions and the binding positions between the target and the inhibitor [2,11] Therefore, the study aimed to evaluate the binding profile of protein–ligand inhibitor complex, and carry out structure based design of new potent compounds via Computer-aided virtual screening.

2. Methods

2.1. Collection of dataset

Thirty six synthesized compound comprising the analogues of quinoline in the present study were accessed from the work reported in the literature [8]. The chemical structure of all the quinoline analogues were presented in Table 1.

![Crystal structure of DNA gyrase](image)

**Table 1 (continued)**

| S/N | Molecular structure | Compound nomenclature                                                                 | Percentage inhibition (%) |
|-----|---------------------|---------------------------------------------------------------------------------------|--------------------------|
| 34  | ![Molecular structure](image) | (E)-(2-(2-(4-methoxybenzylidene)hydrazinyl)quinolin-4-yl)(4-methylpiperazin-1-yl)methanone | 30                       |
| 35  | ![Molecular structure](image) | (E)-N-phenyl-2-((2-(thiophen-2-ylmethylene)hydrazinyl)quinolin-4-carboxamide)           | 26                       |
| 36  | ![Molecular structure](image) | (E)-N-phenyl-2-((2-(pyridin-4-ylmethylene)hydrazinyl)quinolin-4-carboxamide)             | 14                       |

Fig. 1. Crystal structure of DNA gyrase.
Table 2
Analysis of protein-inhibitor docking interactions between DNA gyrase and quinoline analogues.

| Ligand ID | Binding Affinity (BA) Kcal/mol | Hydrogen bond Hydrophobic interaction | Target protein | Bond length (Å) | Residual target |
|-----------|--------------------------------|--------------------------------------|----------------|-----------------|-----------------|
| 1         | −7.2                           | [PRO124]                             |                | 2.251           | VAL278, TRP103, HIS220, GLN277 |
| 2         | −7.5                           | [ARG98]                              |                | 2.9399          | GLN277, PRO285, HIS220, VAL78  |
| 3         | −7.7                           | [ASP94]                              | [TRP182]       | 2.3878          | PRO124, VAL138, GLN101, CYS112 |
| 4         | −7.7                           | [ARG98]                              | PRO124, VAL97, HIS220 | 1.4999         |
| 5         | −7.9                           | [ASP94]                              | PRO124, VAL97, HIS220 | 2.1801         |
| 6         | −8.3                           | [SER102]                             | ASP122, ALA167, TRP182, SER247 | 2.529         |
| 7         | −8.2                           | [ARG98]                              | ARG98, CYS156, ASP256 | 4.287         |
| 8         | −13.4                          | [HIS220]                             |                | 2.4765          | PHE228, ALA173, PRO119, TRP182, SER247 |
| 9         | −8.4                           | [LEU213]                             |                | 1.461           | MET99, VAL78, TRP182, SER118, ASP122, |
| 10        | −8.2                           | [ARG184]                             |                | 2.1738          | ARG98, VAL77, ASP94, VAL182, SER247 |
| 11        | −9.7                           | [ASP94 TRP103]                       | GLY120, SER118, HIS220 | 1.383         |
| 12        | −8.6                           | [SER104]                             | ASP94, PRO285, HIS220 | 2.023         |
| 13        | −8.1                           | [PRO]                                | PRO34, PRO285, HIS220 | 2.221         |
| 14        | −8.4                           | [VAL169]                             | ARG98, SER118, HIS220 | 2.6621         |
| 15        | −9.1                           | [GLY145]                             | ARG134PRO285, HIS220 | 2.4909         |
| 16        | −8.1                           | [ARG94]                              | ARG98, SER118, HIS220 | 3.7071         |
| 17        | −18.8                          | [ARG98]                              | ARG98, SER118, HIS220 | 1.99395       |
| 18        | −9.1                           | [LEU114]                             | LEU164, VAL228, PHE168, GLY232, TYR276 | 2.9893         |
| 19        | −9.7                           | [ALA167]                             | ALA167, ARG94, SER118, HIS220 | 1.3965         |
| 20        | −11.6                          | [MET99]                              | MET99, VAL182, PHE220, LEU156, VAL78 | 2.3975         |
| 21        | −9.9                           | [GLY223]                             | ARG98, LEU103, ALA167, PHE168, MET234, | 2.5093         |
| 22        | −6.8                           | [PHE212]                             | TRP182, HIS220, MET99, SER118, HIS220 | 1.8408         |
| 23        | −10.7                          | [LEU146]                             | TRP182, HIS220, MET99, SER118, HIS220 | 2.1665         |
| 24        | −7.9                           | [ARG94]                              | ARG98, SER118, HIS220, MET99, SER118, HIS220 | 1.5984         |
| 25        | −7.1                           | [TRP182]                             | TRP182, HIS220, MET99, SER118, HIS220 | 2.3663         |
| 26        | −8                             | [PHE256]                             | TRP182, HIS220, MET99, SER118, HIS220 | 1.287          |
| 27        | −9.2                           | [ARG143]                             | ARG98, SER118, HIS220, MET99, SER118, HIS220 | 1.3896         |
| 28        | −8.5                           | [ARG145]                             | ARG145, TRP182, HIS220, MET99, SER118, HIS220 | 1.9217         |
| 29        | −8.1                           | [TRP182]                             | TRP182, HIS220, MET99, SER118, HIS220 | 2.3896         |
| 30        | −8.2                           | [MET99]                              | ARG98, TRP182, HIS220, MET99, SER118, HIS220 | 1.3896         |
| 31        | −9.3                           | [PRO124]                             | TRP182, HIS220, MET99, SER118, HIS220 | 3.1345         |
| 32        | −11.4                          | [TRP276]                             | GLN277, VAL182, HIS220, MET99, SER118, HIS220 | 2.5007         |
| 33        | −7.1                           | [GLN277]                             | ARG98, TRP182, HIS220, MET99, SER118, HIS220 | 3.2896         |
| 34        | −9.6                           | [HIS220]                             | ARG98, TRP182, HIS220, MET99, SER118, HIS220 | 2.5007         |
| 35        | −9.4                           | [TYR276]                             | ARG98, TRP182, HIS220, MET99, SER118, HIS220 | 1.3907         |
| 36        | −8.2                           | [ALA167]                             | ARG98, TRP182, HIS220, MET99, SER118, HIS220 | 1.3979         |

**Ethambutol** | −5.8 | [ALA137] | 2.59739 |
2.2. Procedure for the receptor-ligand docking task

The molecular docking task was done to determine the best ligand binding sites, based on the magnitude of the binding affinity, and types of interactions formed in the stable complex. This was achieved with the aid of AutoDock Vina 4.2 of the PyRx virtual screening software. The crystal structure of DNA gyrase with PDB code 3IFZ (https://www.rcsb.org/structure/3IFZ) as the targeted enzyme was presented in Fig. 1 [12,13]. For the purpose of having a good binding score and reliable residual interaction between the molecules (ligands) and the protein (enzyme), all complexed ligands, solvent molecules, and cofactors in the downloaded enzyme were manually removed using Discovery Studio.

Fig. 2. (8a) and (8b) show the binding interactions between Ligand 8 and the target in term of 3D and 2D analysis. (17a) and (17b) show the binding interactions between Ligand 17 and the target in term of 3D and 2D analysis.

Fig. 3. A and B show the 3D and 2D interactions of the target with ethambutol.
Subsequently, the enzyme protein in (pdb) format was exported to the PyRx tool, then further transformed as macromolecule [2,14,15]. The best conformation of each quinoline derivative (ligand) at lowest energy was determined using Spartan 14 software by utilizing Density Functional Theory [DFT (B3LYP / 631G). Afterwards, all optimized ligands in (.pdb) format were also exported to the PyRx software, then charged as micromolecules [2,11].

The docking task started with the recognition of the binding sites by the setting of grid box size (60 × 60 × 60 along x, y, z axes) which covered the entire protein at a grid spacing of 0.3750Å. Initially, an AutoGrid was performed which generated the grid map for the various atoms of the receptor and ligand. As such, flexible docking simulations were done at the initial population = 50 individuals, the number of energy function evaluations = 2.5 × 10^6, maximum number of generations = 27,000, genetic algorithm (GA) = 50 populations and root mean square (RMS) cluster tolerance of 2.0Å per run. Out of the 50 runs,
10 lowest energy conformers of the complexes were generated accordingly based on the ranking of the binding scores and the lowest energy conformation which was further used for the docking analysis and interpretation. [11,15]

3. Result

3.1. Discussion

Analysis and interpretation of the molecular docking studies of quinolone derivatives in this study with DNA gyrase as the targeted receptor was shown in Table 2. The residual interactions in terms of binding affinity existing between the ligands and the protein binding pocket ranges from (–7.1 to –18.8) kcal/mol. However, when the binding affinity score of ethambutol (–5.8 kcal/mol) as a conventional drug was compared with the scores of the studied quinolone derivatives, it was observed that ligand 8 and 17 have higher binding affinity score of 14.3 and 18.8 kcal/mol than others.

As such, Ligands (compounds 8 and 17) were visualized using Discovery Studio Visualizer to determine their interaction types or nature of binding. The 2D & 3D interactions of ligands 8 and 17 with the receptor target active site were all shown in Fig. 2. Four (4) conventional H-bonds (4.2243, 2.9503, 2.5213 and 2.6301Å) were observed between SER118, ARG98, GLY120 and GLY120 residues and ligand 8. In which, one (1) H-bond was observed with the C = O of the ligand as H-acceptor and linked with ARG98 of the protein active site. Furthermore, the remaining three (3) hydrogen bonds were formed between the N–H group (hydropyridine) as H-donor and GLY120 and one (1) H-bond with SER118 as elucidated in Figure in 2 and 6 respectively. Similarly, hydrophobic interactions was observed between ASP94, VAL97, TYR276 and PRO124 residues of the target site and ligand 8 as shown in Fig. 4.

More also, four (4) conventional hydrogen bonds (1.9128, 3.3701, 2.8704 and 3.2821Å) were formed between GLY120, ARG98, SER118, and GLY120 residues and ligand 17 as shown in Fig. 2. One (1) hydrogen bond was observed between C = O functional group of the ligand as H-acceptor and ARG98 residue of the target. Also, two (2) H-bonds were observed with N–H (hydropyridine) group of the ligand as H-donor with GLY120 of the target. Additional H-bond was observed with N–H group (hydrazine) of the ligand as H-donor with SER118 of the target site as shown in Figs. 2 and 7. Hydrophobic formed interactions with PRO124, VAL97, ASP122, VAL97, ASP94, and PRO123 of the target site as shown in Fig. 5. Analysis of H-bond linked together with the hydrophobic linked offer clear evidence that ligand 8 and 17 of 2, 4-disubstituted quinoline derivatives are potent anti-tubercular agents against the target enzyme (DNA gyrase) (see Fig. 6).

3-D, 2-D and H-bond interactions of the ethambutol as conventional anti-tubercular drug with the protein target were shown in Fig. 3. Only one H-bond (2.59739Å) was observed with ALA337 residue and no any
Table 3
Computed binding affinity for the designed compounds.

| Compound ID | R₁     | R₂     | Binding affinity (Kcal/mol) |
|-------------|--------|--------|----------------------------|
| 17a         | CH₃    |        | -18.4                      |
| 17b         |        |        | -18.9                      |
| 17c         |        |        | -20.5                      |
| 17d         |        |        | -19.7                      |
| 17e         |        |        | -20.1                      |
| 17f         |        |        | -19.6                      |
| 17g         |        | CH₃    | -19.3                      |
| 17h         |        |        | -19.9                      |
| 17i         |        |        | -24.6                      |
| 17j         |        |        | -21.2                      |
| 17k         | CH₃    |        | -20.6                      |
| 17l         | CH₂CH₃ |        | -18.9                      |
| 17m         |        |        | -20.2                      |
| 17n         |        |        | -26.8                      |

(continued on next page)
Table 4
Analysis of protein-inhibitor docking interactions between DNA gyrase and the designed compounds.

| Ligand ID | Binding Affinity (BA) Kcal/mol | Hydrogen bond Hydrophobic interaction |
|-----------|--------------------------------|--------------------------------------|
|           | Target protein Bond length (Å) Residual Amino acid |                                    |
| 17i       | TRP A103 2.43 ASP A122, PRO A124, ASP A94 |                                     |
| 17j       | TRP A103 2.10 ARG A98, VAL A97, PRO A124, PRO A119 |                                     |
| 17n       | TRP A103 2.50 ARG A98, VAL A97, PRO A124, PRO A119 |                                     |

Fig. 9. 3-Dimensional interactions between the target and designed ligand 17i, 17j and 17n and the target.
hydrophobic interactions which could be responsible for the low binding affinity (−5.8 kcal/mol) in the study. Therefore, increase in number of hydrogen bonds observed in ligands 8 and 17 of quinoline analogues gives reasonable suggestion as to why higher binding affinities (−18.4 and −18.8 kcal/mol) were computed for ligands 8 and 17 compared to low binding affinity (−5.8 kcal/mol) computed for ethambutol.

3.2. Binding analysis of the designed compounds

Substitution, deletion and insertion techniques were employed to designed some novel anti-tubercular agents with enhanced activities [1, 2, 16, 17, 18] via modification of the template structure (E)-N-benzyl-2-(2-benzylidenehydrazinyl)quinoline-4-carboxamide (i.e. compound 17) presented in Fig. 8a using the approach of structure based design. The template was selected as the reference compound and backbone to designed new promising compounds due to its prominent binding affinity reported in Table 2. The discovery of the new compounds was successfully achieved based on the information derived from the binding interaction of the lead compound 17 with the target enzyme. The modification of the template was successfully made by substitution and deletion of N-ethylacetamide and 2-methylhydrazine moiety of the template at position 18 and 26 shown in Fig. 8b which leads to generation of fourteen prominent compounds with improved anti-tubercular activities as present in Table 3. Meanwhile, compound 17i, 17j and 17n were observed with high activities among the designed compounds. This was as a result of N-substituted alkyl amine substituted at position 16 and 26 of the reference template acting as electron donating substituents via positive inductive effect (+I). The inductive effect (+I) makes the nitrogen strongly electronegative thereby making the lone pair of electron on N-atom is easily available. The steric hindrance of the bulky alkyl group (3° amine) observed in the compound 17j account for the decrease in its reactivity when compared to compound 17i (1° amine) and 17n (2° amine). Based on the decreasing order of amine; (CH₃)₂NH > CH₃NH₂ > (CH₃)₃N > NH₃, suggests why compound 17n was observed with prominent activity. Modification and variation of quinoline reference template (compound 17) at position 18 and 24 lead to development of fourteen new ligands with which were designed ligands 17i, 17j and 17n were computed with improved binding affinity against receptor DNA gyrase. The binding interaction of the docked receptor-ligand result of ligand 17i, 17j and 17n ranges from (−21.2 to −26.8) kcal/mol as reported in Table 4 which were greater than the binding interaction (−18.8 kcal/mol).
mol) for template 17 reported in Table 2.

Five conventional H-bond interactions with target site were observed with Ligand 17i. The ligand C = O acts as H-acceptor with TRP103 and GLU101 and made two hydrogen bonds. The (hydro-pyridine) N–H group acts as H-donor and made two successful H-bonds with ARG98 and ASP94 of the target. More also, the N–H group of N-substituted amine act as H-atom donor and formed one H-bond with ALA90 of the target as shown in Figs. 9 and 10.

Four H-bonds interactions with target site were observed with Ligand 17j. Two H-bonds linking GLU101 and TRP103 of the target were observed with C = O of the ligand acting as H-acceptor. Meanwhile, N–H group (hydro-pyridine) of the ligand acting as H-donor was observed with two H-bonds with ASN121 and GLY120 as shown in Figs. 9 and 10.

Seven conventional H-bonds interactions with target site were observed with Ligand 17n. Two H-bonds formation were observed with the hydrazine (N–H group) as H-atom donor with GLA101 and SER118 of the target. Meanwhile, another two H-bonds were observed with N–H group of N-substituted amine of the ligand as H-atom donor with ALA90 and PRO A:119 of the target. In addition, The N–H group of the quinoline pharmacophore acts as H-donor with formation of two H-bonds conventional with SER118 and GLY120 of the target. Whereas, single H-bond formation was made with C = O acting as H-bond with ARG98 of the target as shown in Figs. 9 and 10. Meanwhile Figs. 11 and 12 shows the H-bond and hydrophobic picture for better explanation of the interaction of the designed and the target.

Reference to observation and information recorded above in term of binding affinities and interaction types provide concrete confirmation that increase in the number of hydrogen bonds formation observed in ligand 17i, 17j and 17n accounts for their potency against DNA gyrase target [9,11,16–18] compared to the template ligand 17 of quinoline.

4. Conclusion

Computer-aided virtual screening of quinoline analogues, structure based design and analysis of protein-ligand binding interaction have been analyzed and established via molecular docking simulation. The inhibition efficiency of the paramount compound (i.e. ligand ID 17) with noticeable binding affinity of −18.8 kcal/mol was identified to be greater than that of commended drug ethambutol (−5.8 kcal/mol) when compared. Reference to this, compound 17 was adopted as a model template and mainstay to design some novel proposed compounds with enhance and better efficacy. This template was successfully executed to design fourteen compounds with higher binding affinities. Meanwhile, designed compound 17i, 17j and 17n with lead binding affinities among the designed compounds have the most perceptible binding affinity ranges from (−21.2 to −26.8) kcal/mol. Therefore the facts obtained in this findings give a clear direction for further studies such as molecular dynamic simulation on the protein-inhibitor complex interactions with high specificities and also recommend toxicity evaluation of the designed compounds via pharmacokinetic studies.
5. Accessibility of data and material

It has been reported in the manuscript.

Ethical statement

Not applicable.

Funding

None.

CRediT authorship contribution statement

Gideon Adamu Shallangwa: Conceptualization, Methodology, Data curation, Visualization, Investigation, Supervision, Writing - review & editing. Shola Elijah Adeniji: Conceptualization, Methodology, Data curation, Writing - original draft.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgement

None.

References

[1] Adeniji SE, Arthur DE, Abdullahi M, Haruna A. Quantitative structure-activity relationship model, molecular docking simulation and computational design of some novel compounds against DNA gyrase receptor. Chem Africa 2020;3(2):391–408. https://doi.org/10.1007/s42250-020-00132-9.

[2] Adeniji SE, Arthur DE, Abdullahi M, Abdullahi A, Ugbe FA. Computer-aided modeling of triazole analogues, docking studies of the compounds on DNA gyrase enzyme and design of new hypothetical compounds with efficient activities. J Biomol Struct Dyn 2020;9:1–18. https://doi.org/10.1080/07391102.2020.1852963.

[3] Abdullahi M, Adeniji SE, Arthur DE, Haruna A. Homology modeling and molecular docking simulation of some novel imidazo[1,2-a]pyridine-3-carboxamide (IPA) series as inhibitors of Mycobacterium tuberculosis. J Genet Eng Biotechnol 2021;19:12. https://doi.org/10.1186/s43141-020-00102-1.

[4] James CW. DNA Entanglement and the Action of the DNA Topoisomerases. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2009. p. 245.

[5] Huang YY, Deng JY, Gu J, Zhang ZP, Maxwell A, Bi LJ, Chen YY, Zhou YF, Yu ZN, Zhang XE (2006) The key DNA-binding residues in the C-terminal domain of Mycobacterium tuberculosis DNA gyrase A subunit (GyrA). Nucleic Acids Research. 34: 5650–5659.

[6] Zhang Y, Post-Martens K, Denkin S. New drug candidates and therapeutic targets for tuberculosis therapy. Drug Discovery Today 2006;11(1-2):21–7.

[7] Adeniji SE, Adalumo OB. Computational modeling and ligand-based design of some novel hypothetical compound as prominent inhibitors against. Future J Pharm Sci 2020;6:15. https://doi.org/10.1186/s43094-020-00027-z.

[8] Nayyar A, Jain R. Synthesis and anti-tuberculosis activity of 2, 4-disubstituted quinolines. Indian J Chem 2008;47:117–28.

Fig. 12. Hydrophobic interactions between the target and designed ligand 17i, 17j and 17n and the target.
[9] Adeniji SE. Genetic functional algorithm model, docking studies and in silico design of novel proposed compounds against Mycobacterium tuberculosis. Egyptian J Basic Appl Sci 2020;7(1):292–314.

[10] Adeniji SE, Adamu Shallangwa G, Ebaka Arthur D, Abdullahi M, Mahmoud AY, Haruna A. Quantum modelling and molecular docking evaluation of some selected quinoline derivatives as anti-tubercular agents. Helion 2020;6(3):e03639. https://doi.org/10.1016/j.jhelion.2020.e03639.

[11] Adeniji SE, Adalumo OB, Ekoja FO. Anti-tubercular modelling, molecular docking simulation and insight toward computational design of novel compounds as potent antagonist against DNA gyrase receptor. Med Microcol 2020;5:100020. https://doi.org/10.1016/j.medmic.2020.100020.

[12] Piton J, Petrella S, Delarue M, André-Leroux G, Jarlier V, Aubry A, Mayer C. Structural Insights into the Quinoline Resistance Mechanism of Mycobacterium tuberculosis DNA Gyrase. PLoS ONE 2010;5:e12245. https://doi.org/10.1371/journal.pone.0012245.

[13] Piton J, Petrella S, Delarue M, André-Leroux G, Jarlier V, Aubry A, Mayer C. (2010) Structural Insights into the Quinoline Resistance Mechanism of Mycobacterium tuberculosis DNA Gyrase, https://www.rcsb.org/structure/3IFZ.

[14] Abdullahi M, Adeniji SE. In-silico molecular docking and ADME/pharmacokinetic prediction studies of some novel carboxamide derivatives as anti-tubercular agents. Chem Africa 2020;3(4):989–1000. https://doi.org/10.1007/s42250-020-00162-3.

[15] Abdullahi M, Shallangwa GA, Uzairu A. In silico QSAR and molecular docking simulation of some novel aryl sulfonamide derivatives as inhibitors of H5N1 influenza A virus subtype. Beni-Suef University. J Basic App Sci 2020;9:1–13.

[16] Patil R, Das S, Ashley S, Yadav L, Sudhakar A, Ashok KV, et al. Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing. PLoS ONE 2010;8:1–10.

[17] Adedirin O, Uzairu A, Shallangwa GA, Abecchi SE. A novel QSAR model for designing, evaluating, and predicting the anti-MES activity of new 1H-pyrazole-5-carboxylic acid derivatives. J Turk Chem Soc 2017;4:739–74.

[18] Adeniji SE, Arthur DE, Abdullahi M, Adalumo OB. Computational investigation, virtual docking simulation of 1, 2, 4-Triazole analogues and in silico design of new proposed agents against protein target (3IFZ) binding domain. Bull National Res Centre 2020;44:132.